Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management
F. Tetart,S. Walsh,B. Milpied,K. Gaspar,A. Vorobyev,G. S. Tiplica,B. Didona,A. Welfringer‐Morin,V. Kucinskiene,B. Bensaid,E. Marvanova,C. Salavastru,E. Brezinova,S. L. Chua,M. L. Lovgren,C. M. Hammers,A. Barbaud,C. G. Mortz,B. Horvath,D. Meyersburg,B. Lebrun‐Vignes,C. Bodemer,M. C. Brüggen,L. E. French,S. Ingen‐Housz‐Oro
DOI: https://doi.org/10.1111/jdv.20232
2024-07-20
Journal of the European Academy of Dermatology and Venereology
Abstract:Acute generalized exanthematous pustulosis (AGEP) is a rare, usually drug‐induced, acute pustular rash. Despite the lack of strong data supporting the effectiveness of topical or systemic corticosteroids in this drug reaction, they are widely used. More generally, there is no consensus on the diagnostic modalities and the management of patients with AGEP. We aimed to provide European expert recommendations for the diagnosis and management or patients with AGEP. Members of the ToxiTEN group of the European Reference Network (ERN)‐skin, all dermatologists and/or allergologists with expertise in drug reactions, elaborated these recommendations based on their own experience and on a review of the literature. Recommendations were separated into the following categories: professionals involved, assessment of the diagnosis of AGEP, management of the patient and allergological work‐up after the acute phase. Consensus was obtained among experts for the list of professionals involved for the diagnosis and management of AGEP, including the minimum diagnostic work‐up, the setting of management, the treatments, the modalities and the timing of allergological work‐up and follow‐up. European experts in drug allergies propose herein consensus on the diagnosis and management of patients with AGEP. A multidisciplinary approach is warranted, including dermatologists, allergologists and pharmacovigilance services.
dermatology